Antiproliferative activity of novel benzo[b][1,6]naphthyridines in human solid tumor cell lines

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 5, 2010, Pages 1504-1506

  Rudys, Simonas ^a   Ríos Luci, Carla ^b   Pérez Roth, Eduardo ^b   Cikotiene, Inga ^a   Padrón, José M ^b,c  

^a VILNIUS UNIVERSITY   (Lithuania)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c Facultad de Ciencias Farmacéuticas y Bioquímicas   (Spain)

Author keywords

1H Pyrano 4,3 b quinolines; Antibacterial drugs; Antifungal drugs; Antitumor drugs; Benzob 1,6 naphthyridines; Multicomponent reaction

Indexed keywords

1,2 DIHYDRO 3 PHENYL 1 (TRICHLOROMETHYL)BENZO[B][1,6]NAPHTHYRIDINE DERIVATIVE; 2 ETHOXY 1H PYRANO[4,3 B]QUINOLINE DERIVATIVE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; NAPHTHYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL STRAIN; CANCER CELL CULTURE; CANCER INHIBITION; CANDIDA; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SYNTHESIS; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; FUNGAL STRAIN; HUMAN; HUMAN CELL; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MITOSIS INHIBITION; NONHUMAN; PSEUDOMONAS AERUGINOSA; SOLID TUMOR; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NAPHTHYRIDINES;

CANDIDA;

EID: 76649107653     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.01.112     Document Type: Article

References (39)

1. Sirisoma N., Pervin A., Zhang H., Jiang S., Willardsen J.A., Anderson M.B., Mather G., Pleiman C.M., Kasibhatla S., Tseng B., Drewe J., and Cai S.X. J. Med. Chem. 52 (2009) 2341
2. Krug M., and Hilgeroth A. Mini-Rev. Med. Chem. 8 (2008) 1312
3. Pédeboscq S., L'Azou B., Passagne I., De Giorgi F., Ichas F., Pometan J.P., and Cambar J. J. Exp. Ther. Oncol. 7 (2008) 99
4. Zhang Y., and Xu W. Anticancer Agents Med. Chem. 8 (2008) 698
5. Jantova S., Repicky A., Paulovicova E., Letasiova S., and Cipak L. Exp. Oncol. 30 (2008) 139
6. Welch S.A., and Moore M.J. Future Oncol. 3 (2007) 247
7. Herbst R.S., and Kies M.S. Clin. Adv. Hematol. Oncol. 1 (2003) 466
8. Denny W.A. Farmaco 56 (2001) 51
9. Srivastava S.K., Jha A., Agarwal S.K., Mukherjee R., and Burman A.C. Anticancer Agents Med. Chem. 7 (2007) 685
10. Sissi C., and Palumbo M. Curr. Med. Chem. Anticancer Agents 3 (2003) 439
11. Hradil P., Hlavác J., Soural M., Hajdúch M., Kolár M., and Vecerová R. Mini-Rev. Med. Chem. 9 (2009) 696
12. Xia Y., Yang Z.Y., Morris-Natschke S.L., and Lee K.H. Curr. Med. Chem. 6 (1999) 179
13. Kumar V., Jaggi M., Singh A.T., Madaan A., Sanna V., Singh P., Sharma P.K., Irchhaiya R., and Burman A.C. Eur. J. Med. Chem. 44 (2009) 3356
14. Andaloussi M., Moreau E., Masurier N., Lacroix J., Gaudreault R.C., Chezal J.M., El Laghdach A., Canitrot D., Debiton E., Teulade J.C., and Chavignon O. Eur. J. Med. Chem. 43 (2008) 2505
15. Ruchelman A.L., Singh S.K., Ray A., Wu X.H., Yang J.M., Li T.K., Liu A., Liu L.F., and LaVoie E.J. Bioorg. Med. Chem. 11 (2003) 2061
16. Li T.K., Houghton P.J., Desai S.D., Daroui P., Liu A.A., Hars E.S., Ruchelman A.L., LaVoie E.J., and Liu L.F. Cancer Res. 63 (2003) 8400
17. León L.G., Carballo R.M., Vega-Hernández M.C., Martín V.S., Padrón J.I., and Padrón J.M. Bioorg. Med. Chem. Lett. 17 (2007) 2681
18. Padrón J.M., Tejedor D., Santos-Expósito A., García-Tellado F., Martín V.S., and Villar J. Lett. Drug Des. Discov. 2 (2005) 529
19. Padrón J.M., Tejedor D., Santos-Expósito A., García-Tellado F., Martín V.S., and Villar J. Bioorg. Med. Chem. Lett. 15 (2005) 2487
20. Asao N., Iso K., and Yudha S.S. Org. Lett. 8 (2006) 4149
21. Ding Q., Wang B., and Wu J. Tetrahedron 63 (2007) 12166
22. Sun W., Ding Q., Sun X., Fan R., and Wu J. J. Comb. Chem. 9 (2007) 690
23. Iso K., Yudha S.S., Menggenbateer, and Asao N. Heterocycles 74 (2007) 649
24. Cikotiene I., Kairys V., Buksnaitiene R., Morkunas M., Motiejaitis D., Rudys S., Brukstus A., and Fernandes M.X. Tetrahedron 65 (2009) 5760
25. Cikotiene I., Morkunas M., Motiejaitis D., Rudys S., and Brukstus A. Synlett (2008) 1693
26. Cikotiene I., and Morkunas M. Synlett (2009) 284
27. Cikotiene I. Tetrahedron Lett. 50 (2009) 2570
28. General procedure for the synthesis of 2-substituted 1,2-dihydro-3-phenyl-1-(trichloromethyl)benzo[b]-[1,6]naphthyridines (2) and N-[(1E)-[2-(phenylethynyl)-3-quinolinyl]methylene]benzen-amine (3): To a mixture of 1 (0.1 g, 0.39 mmol) and 3 Å MS (0.3 g) in chloroform (3 mL) the corresponding amine (0.39 mmol) was added. The reaction mixture was refluxed for 24-48 h. After reaction completion as observed by TLC, the solvent was evaporated to leave the crude product, which was purified by basic silica gel column chromatography using a mixture of toluene and ethyl acetate as an eluent to give 2a-f and 3.
29. 2: C, 86.72; H, 4.85; N, 8.43. Found: C, 86.91; H, 4.77; N, 8.49.
30. Godet T., Vaxelaire C., Michel C., Millet A., and Belmont P. Chem. Eur. J. 13 (2007) 5632
31. 2: C, 78.87; H, 5.23; N, 4.84. Found: C, 79.00; H, 5.25; N, 4.92.
32. Formation of 5-endo-dig cyclization product requires the presence of a base. See:. Kanazawa C., Ito A., and Terada M. Synlett (2009) 638
33. Wei L.L., Wei L.M., Pan W.B., and Wu M.J. Synlett (2004) 1497 and Refs. 6b and 12
34. Cikotiene I., Buksnaitiene R., Rudys S., Morkunas M., and Motiejaitis D. Tetrahedron 66 (2010) 251
35. The more detailed investigation of regioselectivity of acetalisation-cyclization reactions of 2-alkynylquinoline-3-carbaldehydes together with data of NMR and molecular modeling will be published in due course.
36. Miranda P.O., Padrón J.M., Padrón J.I., Villar J., and Martín V.S. ChemMedChem 1 (2006) 323
37. Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C., Langley J., Cronice P., Vaigro-Wolf M., Gray-Goodrich M., Campbell H., and Mayo M.R. J. Natl. Cancer Inst. 83 (1991) 757
38. 50 was established as the concentration of compound that inhibited 50% growth when compared to untreated cells.
39. DeLeo F.R., and Chambers H.F. J. Clin. Invest. 119 (2009) 2464